Elad Asher։ STORM-PE Shows Functional Benefits of Thrombectomy
Elad Asher, Professor of Medicine at Shaare Zedek Medical Center, shared a post on LinkedIn about a recent article by Rachel P. Rosovsky et al, published in JACC: Cardiovascular Interventions, adding:
”Reperfusion in intermediate-high risk pulmonary embolism has always had an evidence problem: the endpoints that moved were anatomic, and the endpoints patients care about were never tested in a randomized trial.
The STORM-PE 90-day report in JACC Cardiovascular Interventions is the first attempt to close that gap.
One hundred patients at 22 international sites were randomized 1:1 to computer-assisted vacuum thrombectomy with anticoagulation, or anticoagulation alone. The trial’s primary endpoint, reported separately in Circulation in 2025, was the change in RV/LV ratio at 48 hours.
This paper reports functional, quality-of-life and safety outcomes through 90 days.
The functional signal is real and it is large. Six-minute walk distance was 478.7 plus or minus 159.5 metres with thrombectomy against 368.0 plus or minus 127.8 metres, with a p-value of 0.003. NYHA class I at 90 days was 97.4 percent (37 out of 38) against 75.6 percent (34 out of 45), with a p-value of 0.005. Dyspnea and quality-of-life scores were comparable, and there was no difference in all-cause mortality, PE-related mortality or symptomatic recurrence.
Now the part that decides how much weight this carries. The walk test was completed by 31 of 47 patients in the thrombectomy arm and 34 of 53 in the anticoagulation arm. Roughly a third of each arm is absent from the headline endpoint, and in a walk test, non-completion is not random: the patients who cannot manage the corridor are the ones whose distance you most need. Add nequal to 100, secondary endpoints, and means with standard deviations but no confidence intervals, and this is a signal worth pursuing rather than a settled answer.
It is still the first randomized evidence that catheter reperfusion changes how these patients function months later, and that is not nothing.
What would convince you – a larger trial, or complete follow-up on this one?”
Title: Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE: Improved Functional 90-Day Outcomes in STORM-PE RCT
Authors: Rachel P. Rosovsky, Stavros V. Konstantinides, Ido Weinberg, Suhail Y. Dohad, Zachary Rosol, Jakub Stępniewski, John M. Moriarty, Sahil A. Parikh, Andrew Holden, Richard N. Channick, Braedon McDonald, Khanjan H. Nagarsheth, Yuri Matusov, Robert A. Lookstein, the STORM-PE Trial Investigators and Collaborators

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 6, 2026, 22:40Panama Achieves Self-Sufficiency in Haemophilia Care – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
-
Nov 6, 2026, 22:31Luisa Weiss: Exploring the Role of Platelets and Extracellular Vesicles in Calcific Aortic Valve Disease
-
Nov 6, 2026, 22:29Nour Al-Mozain: The Role of Therapeutic Apheresis and Cell Therapy in Advancing Regional Practice
-
Nov 6, 2026, 22:28Moazzam Shahzad: Celebrating Mentees Receiving the 2026 ASH Abstract Achievement Award
-
Nov 6, 2026, 22:25Habib Bennaceur: Self-Sufficiency in Haemophilia Care – A Major Achievement for Panama
-
Nov 6, 2026, 22:25Alessandro Lucchesi: Engineering Disease Trajectories in Myeloproliferative Neoplasms at RiseMPN 2026
-
Nov 6, 2026, 22:24Davood Bava: A New Practical Handbook for Advances in Transfusion Medicine
-
Nov 6, 2026, 22:15Dmitrii Kalinin: Allosteric Anticoagulation – An Alternative Strategy for Safer, Next-Generation Anticoagulants
-
Nov 6, 2026, 15:11Sophia Delicou: Discussing Real World Mitapivat Case Studies at the 37th Panhellenic Hematology Congress